G6PDi-1

G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells[1].

Product Specifications

CAS Number

[2457232-14-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PDI

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/g6pdi-1.html

Purity

99.53

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

N#CC1=CC(NC2=NC=C(C(CCCC3)=O)C3=N2)=CS1

Molecular Formula

C14H12N4OS

Molecular Weight

284.34

Precautions

H302, H315, H319, H335

References & Citations

[1]Jonathan M Ghergurovich, et al. A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. Nat Chem Biol. 2020 Jul;16 (7) :731-739.|[2]Watermann P, et al. G6PDi-1 is a Potent Inhibitor of G6PDH and of Pentose Phosphate pathway-dependent Metabolic Processes in Cultured Primary Astrocytes. Neurochem Res. 2023 Oct;48 (10) :3177-3189.|[3]Ding H, et al. Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition. Sci Adv. 2021 Nov 19;7 (47) :eabk1023.